P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor with low cytotoxicity, demonstrating significant multidrug resistance (MDR) reversal activity against doxorubicin in MCF7/ADR cells. It has an IC50 value of 0.11 μM and a resistance reversal factor (RF) of 215.9. P-gp-IN-32 interacts directly with P-gp, inducing conformational changes and inhibiting its efflux function. This compound is applicable in cancer research, including studies on breast cancer.

P-gp-IN-32 (Compound BP3p) at a concentration of 5 μM exhibits a growth inhibition rate of less than 25% in both MCF-7 and MCF-7/ADR cells. When used in combination with Doxorubicin in MCF-7/ADR cells, P-gp-IN-32 results in a Doxorubicin IC50 of 0.11 μM and a resistance reversal factor of 215.9. The compound also increases the accumulation of Rhodamine 123 in MCF-7/ADR cells in a dose-dependent manner at concentrations of 2.5-5 μM over 4 hours. However, P-gp-IN-32 at 0.5-5 μM over 48 hours does not significantly affect the expression of P-gp in MCF-7/ADR cells. Additionally, at 50 μM, it enhances the binding of the UIC-2 antibody to P-gp in the same cell line. Finally, using 5 μM P-gp-IN-32 over 5 days in conjunction with Doxorubicin reduces the volume of MCF-7/ADR three-dimensional tumor spheroids.